This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casarini, D. E. Articles by Ribeiro, A. B. Search for Related Content PubMed PubMed Citation Articles by Casarini, D. E. Articles by Ribeiro, A. B.

(Hypertension. 1995;26:1145-1148.)
© 1995 American Heart Association, Inc.

Articles

Calcium Channel Blockers as Inhibitors of Angiotensin I–Converting Enzyme

Dulce E. Casarini; Adriana K. Carmona; Frida L. Plavnik; Maria T. Zanella; Luiz Juliano; Artur B. Ribeiro

From the Department of Medicine, Divisions of Nephrology (D.E.C., F.L.P., A.B.R.) and Endocrinology (M.T.Z.), and Department of Biophysics (A.K.C., L.J.), Escola Paulista de Medicina, Universidade Federal de São Paulo (Brazil).

Correspondence to Dulce E. Casarini, Department of Medicine, Division of Nephrology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 740, 04023-062, São Paulo, SP, Brazil.

Abstract Using ion-exchange chromatography of dialyzed human urine from healthy and hypertensive patients, we detected two peaks of angiotensin I–converting enzyme (ACE) activity on hippuryl-His-Leu eluted at ionic strengths of 0.7 (F1 peak) and 1.25 (F2 peak) mS. These hydrolytic activities decreased gradually in the urine of patients submitted to isradipine treatment, F2 and F1 disappearing after 12 and 24 hours, respectively. By Western blot analysis, the urine fractions corresponding to both peaks from healthy and untreated patients presenting ACE activity and from treated patients (24 hours) without this activity were recognized by an ACE-specific antibody. These results indicated that ACE was present but inhibited in the urine of isradipine-treated patients. In vitro assays with ACE isolated from human urine and guinea pig plasma demonstrated that the enzyme is inhibited by isradipine and other commercially available calcium channel blockers, such as felodipine, nifedipine, and verapamil. A noncompetitive inhibition was observed with all calcium channel blockers studied. In conclusion, these results suggest that besides the primary effect on calcium channels, the more commonly used calcium channel blockers are also ACE inhibitors. The development of efficient calcium channel blockers with higher ACE inhibitory activity could result in interesting bifunctional antihypertensive drugs.

Key Words: angiotensin-converting enzyme • calcium channel blockers • isradipine

This article has been cited by other articles:

				F. A Ronchi, M.-C. Irigoyen, and D. E Casarini Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 34 - 41. [Abstract] [PDF]

				M. C. Camargo de Andrade, G. S. Di Marco, V. de Paulo Castro Teixeira, R. A. Mortara, R. A. Sabatini, J. B. Pesquero, M. A. Boim, A. K. Carmona, N. Schor, and D. E. Casarini Expression and localization of N-domain ANG I-converting enzymes in mesangial cells in culture from spontaneously hypertensive rats Am J Physiol Renal Physiol, February 1, 2006; 290(2): F364 - F375. [Abstract] [Full Text] [PDF]

				G. D.M. Marques, B. M.R. Quinto, F. L. Plavinik, J. E. Krieger, O. Marson, and D. E. Casarini N-Domain Angiotensin I-Converting Enzyme With 80 kDa as a Possible Genetic Marker of Hypertension Hypertension, October 1, 2003; 42(4): 693 - 701. [Abstract] [Full Text] [PDF]